Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future
Authors
Keywords
-
Journal
Cells
Volume 10, Issue 1, Pages 117
Publisher
MDPI AG
Online
2021-01-11
DOI
10.3390/cells10010117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
- (2020) G. A. Horne et al. LEUKEMIA
- CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
- (2020) Ross Kinstrie et al. LEUKEMIA
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
- (2020) Tun Kiat Ko et al. BLOOD
- Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
- (2020) Yazad D. Irani et al. BRITISH JOURNAL OF HAEMATOLOGY
- Response and Resistance to BCR-ABL1-Targeted Therapies
- (2020) Theodore P. Braun et al. CANCER CELL
- Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors
- (2020) Katharina Rothe et al. Cell Stem Cell
- Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
- (2020) Rahul Kumar et al. LEUKEMIA
- Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
- (2019) Maja Kim Kuepper et al. LEUKEMIA
- Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells
- (2019) Puneet Agarwal et al. Cell Stem Cell
- The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors
- (2019) Mariella D’Adda et al. CANCER
- The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis
- (2019) Parimala Sonika Godavarthy et al. HAEMATOLOGICA
- Chronic myeloid leukemia stem cells
- (2019) Mohammad Houshmand et al. LEUKEMIA
- Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
- (2019) Bing Z. Carter et al. HAEMATOLOGICA
- Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway
- (2019) Xiaoyan Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- SIRT1 regulates metabolism and leukemogenic potential in CML stem cells
- (2019) Ajay Abraham et al. JOURNAL OF CLINICAL INVESTIGATION
- Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment
- (2019) Alessandra Trojani et al. PLoS One
- MicroRNA signature refine response prediction in CML
- (2019) Raquel Alves et al. Scientific Reports
- KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells
- (2019) Chun Shik Park et al. BLOOD
- Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia
- (2018) Stuart L. Goldberg et al. Clinical Lymphoma Myeloma & Leukemia
- Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
- (2018) Naoto Takahashi et al. HAEMATOLOGICA
- The bone marrow microenvironment in health and disease at a glance
- (2018) Rahul Kumar et al. JOURNAL OF CELL SCIENCE
- Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
- (2018) Naoto Takahashi et al. HAEMATOLOGICA
- Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
- (2018) Monica Bocchia et al. Frontiers in Oncology
- BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
- (2018) Klara Srutova et al. HAEMATOLOGICA
- Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
- (2018) Pablo Baquero et al. LEUKEMIA
- Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition
- (2018) Danna Wei et al. LIFE SCIENCES
- Expression of CD25 on leukemic stem cells in BCR-ABL1 + CML: Potential diagnostic value and functional implications
- (2017) Irina Sadovnik et al. EXPERIMENTAL HEMATOLOGY
- CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
- (2017) Niklas Landberg et al. HAEMATOLOGICA
- Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
- (2017) C Schütz et al. LEUKEMIA
- Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
- (2017) H Zhou et al. LEUKEMIA
- Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia
- (2017) Mathilde Ruggiu et al. LEUKEMIA & LYMPHOMA
- Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia
- (2017) Ayuna Hattori et al. NATURE
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
- (2017) Elodie M Kuntz et al. NATURE MEDICINE
- Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
- (2017) Alice Giustacchini et al. NATURE MEDICINE
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
- (2017) Niklas Landberg et al. HAEMATOLOGICA
- Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia
- (2017) Hyang-Min Byun et al. Open Medicine
- ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells
- (2016) Maria Karvela et al. Autophagy
- Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases
- (2016) Y. Dasgupta et al. BLOOD
- Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells
- (2016) B. Zhang et al. BLOOD
- Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
- (2016) P. Jain et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells
- (2016) Yasufumi Matsuda et al. CANCER SCIENCE
- Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche
- (2016) Haobin Ye et al. Cell Stem Cell
- The biology and function of exosomes in cancer
- (2016) Raghu Kalluri JOURNAL OF CLINICAL INVESTIGATION
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
- (2016) Hannah Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
- (2016) M Ilander et al. LEUKEMIA
- Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
- (2016) Sheela A. Abraham et al. NATURE
- Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
- (2016) Bing Z. Carter et al. Science Translational Medicine
- Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
- (2016) M. T. Scott et al. Cancer Discovery
- Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
- (2016) Jean Claude Chomel et al. Oncotarget
- Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
- (2016) David A. Irvine et al. Scientific Reports
- Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia
- (2015) Xian Zeng et al. Autophagy
- Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells
- (2015) Robert S. Welner et al. CANCER CELL
- Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
- (2015) A Burchert et al. LEUKEMIA
- Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway
- (2015) Wei-Zhang Wang et al. LEUKEMIA RESEARCH
- Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells
- (2015) Kazuhito Naka et al. Nature Communications
- Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche
- (2014) D. S. Krause et al. BLOOD
- BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein
- (2014) A. Agarwal et al. BLOOD
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
- (2014) H. Herrmann et al. BLOOD
- The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells
- (2014) K. Rothe et al. BLOOD
- Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent survival of leukemia cells
- (2014) Chiara Corrado et al. CANCER LETTERS
- Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis
- (2014) Ying-Hua Wang et al. CELL
- Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia
- (2014) SHAN SHAO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
- (2014) M Schmidt et al. LEUKEMIA
- Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
- (2014) K. Beider et al. MOLECULAR CANCER THERAPEUTICS
- Direct measurement of local oxygen concentration in the bone marrow of live animals
- (2014) Joel A. Spencer et al. NATURE
- The growing landscape of lysine acetylation links metabolism and cell signalling
- (2014) Chunaram Choudhary et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells
- (2013) E. Nievergall et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis
- (2013) David Ghez et al. EUROPEAN JOURNAL OF CANCER
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
- (2013) Philippe Rousselot et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
- (2013) Min Chen et al. JNCI-Journal of the National Cancer Institute
- Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
- (2013) F Efficace et al. LEUKEMIA
- Differential regulation of myeloid leukemias by the bone marrow microenvironment
- (2013) Daniela S Krause et al. NATURE MEDICINE
- The mechanisms of Hedgehog signalling and its roles in development and disease
- (2013) James Briscoe et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor
- (2013) K Airiau et al. Cell Death & Disease
- Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
- (2012) A. Agarwal et al. BLOOD
- HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells
- (2012) H. Zhang et al. BLOOD
- Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
- (2012) Ling Li et al. CANCER CELL
- Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
- (2012) Bin Zhang et al. CANCER CELL
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1
- (2012) M T Gómez-Casares et al. ONCOGENE
- Expression and Activity of Fyn Mediate Proliferation and Blastic Features of Chronic Myelogenous Leukemia
- (2012) Melissa M. Singh et al. PLoS One
- Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis
- (2011) H. Yuan et al. BLOOD
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
- (2011) F. Efficace et al. BLOOD
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib
- (2011) Kazuma Ohyashiki et al. BRITISH JOURNAL OF HAEMATOLOGY
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development
- (2011) Damien Reynaud et al. CANCER CELL
- Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia
- (2011) Thomas Schmidt et al. CANCER CELL
- CD34+/CD38- stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin
- (2011) H. Herrmann et al. HAEMATOLOGICA
- Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis
- (2011) Simona Taverna et al. INTERNATIONAL JOURNAL OF CANCER
- p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells
- (2011) L F Peterson et al. LEUKEMIA
- Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
- (2011) E Weisberg et al. LEUKEMIA
- MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib
- (2011) M. Albajar et al. MOLECULAR CANCER RESEARCH
- Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy
- (2010) Dushyant Verma et al. CANCER
- Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
- (2010) Bin Zhang et al. CANCER CELL
- Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia
- (2010) Andrea Hoelbl et al. EMBO Molecular Medicine
- The response to imatinib and interferon- is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
- (2010) F. Palandri et al. HAEMATOLOGICA
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Hedgehog Signaling Is Dispensable for Adult Hematopoietic Stem Cell Function
- (2009) Jie Gao et al. Cell Stem Cell
- Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia
- (2009) Edurne San José-Eneriz et al. EUROPEAN JOURNAL OF CANCER
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family
- (2009) L J Beverly et al. ONCOGENE
- BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia
- (2008) K. Ban et al. BLOOD
- BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia
- (2008) Edurne San José-Enériz et al. BRITISH JOURNAL OF HAEMATOLOGY
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- Immunotherapy for myeloid leukemias: current status and future directions
- (2008) K el-Shami et al. LEUKEMIA
- β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia
- (2008) Y Hu et al. LEUKEMIA
- Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
- (2008) L S Steelman et al. LEUKEMIA
- Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis
- (2008) E K Thomas et al. LEUKEMIA
- CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
- (2008) L. Jin et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More